{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-066896","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2026-06-09T21:26:27+00:00","discovered_at":"2026-06-09T21:28:00.255020+00:00","generated_at":"2026-06-09T21:28:55.148254+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bluejay Diagnostics shareholders approve 600K share increase in stock plan, authorize reverse split","bullets":["Stockholders re-elected all five directors: Chase, Dey, Dey, Wurth, Zeidman.","Approved amendment to 2021 Stock Plan, increasing authorized shares from 61 to 600,061.","Authorized reverse stock split at ratio 1:2 to 1:20; board has no present intention to implement in next 12 months.","Ratified Wolf & Company, P.C. as independent auditor for FY2026.","Stock closed at $4.50 on June 9, compliant with Nasdaq listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-066896","json":"https://secwatch.observer/filing/0001213900-26-066896.json","markdown":"https://secwatch.observer/filing/0001213900-26-066896.md","text":"https://secwatch.observer/filing/0001213900-26-066896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066896/0001213900-26-066896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066896/ea0294209-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:28:55.148254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39cd2c45f08ac0f8f787c5cd2cc32586aec439ff","claim":"Bluejay Diagnostics, Inc. shareholders approved Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026. at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results for the proposal were as follows: Votes For Votes Against Abstentions 389,052 21,067 3,973","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066896/0001213900-26-066896-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"78a9c203afba9542df6c322bd23b87a506d2b6a3","claim":"Bluejay Diagnostics, Inc. shareholders approved Election of Directors - Re-election of Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth and Fred Zeidman to serve until the 2027 annual meeting. at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 1. Election of Directors - The Company’s stockholders re-elected each of Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth and Fred Zeidman to serve as directors until the Company’s 2027 annual meeting of stockholders, or until their successors are duly elected and qualified. The voting results for the proposal were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Donald Chase 207,410 23,558 183,124 Neil Dey 207,842 23,126 183,124 Svetlana Dey 207,327 23,641 183,124 Douglas Wurth 207,337 23,631 183,124 Fred Zeidman 207,334 23,634 183,124","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066896/0001213900-26-066896-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"a966d79c5ee12e05945fbc73f6af44e591b9c579","claim":"Bluejay Diagnostics, Inc. shareholders approved Approve and adopt an amendment to the Company’s stock plan to increase the number of shares available for issuance thereunder from 61 shares to 600,061 shares. at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 3. Approve and adopt an amendment to the Company’s stock plan to increase the number of shares available for issuance thereunder - The Company’s stockholders approved and adopted the Plan Amendment to increase the number of shares of common stock issuable under the Stock Plan by 600,000 (from 61 shares to 600,061 shares). The voting results for the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 135,750 94,058 1,160 183,124","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066896/0001213900-26-066896-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}